{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:36:36Z","timestamp":1790825796883,"version":"4.1.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004543","name":"Chinese Scholarship Council","doi-asserted-by":"crossref","award":["Project No. 201806200107"],"award-info":[{"award-number":["Project No. 201806200107"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The emergence and re-emergence of viral epidemics and the risks of antiviral drug resistance are a serious threat to global public health. New options to supplement or replace currently used drugs for antiviral therapy are urgently needed. The research in the field of ribosomally synthesized and post-translationally modified peptides (RiPPs) has been booming in the last few decades, in particular in view of their strong antimicrobial activities and high stability. The RiPPs with antiviral activity, especially those against enveloped viruses, are now also gaining more interest. RiPPs have a number of advantages over small molecule drugs in terms of specificity and affinity for targets, and over protein-based drugs in terms of cellular penetrability, stability and size. Moreover, the great engineering potential of RiPPs provides an efficient way to optimize them as potent antiviral drugs candidates. These intrinsic advantages underscore the good therapeutic prospects of RiPPs in viral treatment. With the aim to highlight the underrated antiviral potential of RiPPs and explore their development as antiviral drugs, we review the current literature describing the antiviral activities and mechanisms of action of RiPPs, discussing the ongoing efforts to improve their antiviral potential and demonstrate their suitability as antiviral therapeutics. We propose that antiviral RiPPs may overcome the limits of peptide-based antiviral therapy, providing an innovative option for the treatment of viral disease.<\/jats:p>","DOI":"10.1007\/s00018-021-03759-0","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T14:35:40Z","timestamp":1612276540000},"page":"3921-3940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Antiviral activities and applications of ribosomally synthesized and post-translationally modified peptides (RiPPs)"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8074-3722","authenticated-orcid":false,"given":"Yuxin","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7949-9080","authenticated-orcid":false,"given":"Ate H.","family":"Jaarsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-7735","authenticated-orcid":false,"given":"Oscar P.","family":"Kuipers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"3759_CR1","unstructured":"World Health Organization (2018) WHO\u2014The top 10 causes of death. In: 24 Maggio. http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death"},{"key":"3759_CR2","unstructured":"Strauss JH, Strauss EG (2007) Viruses and human disease: Second Edition"},{"key":"3759_CR3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"E De Clercq","year":"2016","unstructured":"De Clercq E, Li G (2016) Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 29:695\u2013747. https:\/\/doi.org\/10.1128\/CMR.00102-15","journal-title":"Clin Microbiol Rev"},{"issue":"12","key":"3759_CR4","doi-asserted-by":"publisher","first-page":"e0208333","DOI":"10.1371\/journal.pone.0208333","volume":"13","author":"V Cagno","year":"2018","unstructured":"Cagno V, Tintori C, Civra A et al (2018) Novel broad spectrum virucidal molecules against enveloped viruses. PLoS ONE 13(12):e0208333. https:\/\/doi.org\/10.1371\/journal.pone.0208333","journal-title":"PLoS ONE"},{"key":"3759_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.tips.2014.06.004","volume":"35","author":"K Wisskirchen","year":"2014","unstructured":"Wisskirchen K, Lucifora J, Michler T, Protzer U (2014) New pharmacological strategies to fight enveloped viruses. Trends Pharmacol Sci 35:470\u2013478. https:\/\/doi.org\/10.1016\/j.tips.2014.06.004","journal-title":"Trends Pharmacol Sci"},{"key":"3759_CR6","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1128\/jvi.00151-09","volume":"83","author":"LW Enquist","year":"2009","unstructured":"Enquist LW (2009) Virology in the 21st Century. J Virol 83:5296\u20135308. https:\/\/doi.org\/10.1128\/jvi.00151-09","journal-title":"J Virol"},{"issue":"3","key":"3759_CR7","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","volume":"55","author":"CC Lai","year":"2020","unstructured":"Lai CC, Shih TP, Ko WC et al (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 55(3):105924. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105924","journal-title":"Int J Antimicrob Agents"},{"key":"3759_CR8","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1016\/j.vaccine.2017.04.082","volume":"35","author":"LA Reperant","year":"2017","unstructured":"Reperant LA, Osterhaus ADME (2017) AIDS, Avian flu, SARS, MERS, Ebola, Zika\u2026 what next? Vaccine 35:4470\u20134474. https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.082","journal-title":"Vaccine"},{"key":"3759_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.idc.2010.01.001","volume":"24","author":"L Strasfeld","year":"2010","unstructured":"Strasfeld L, Chou S (2010) Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am 24:413\u2013437. https:\/\/doi.org\/10.1016\/j.idc.2010.01.001","journal-title":"Infect Dis Clin North Am"},{"issue":"348","key":"3759_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1126\/science.aaa3778","volume":"80","author":"E Bekerman","year":"2015","unstructured":"Bekerman E, Einav S (2015) Combating emerging viral threats: broad-spectrum antiviral drugs are under development to treat emerging viral diseases such as Ebola and dengue for which no specific, licensed treatments exist. Science 80(348):282\u2013283. https:\/\/doi.org\/10.1126\/science.aaa3778","journal-title":"Science"},{"key":"3759_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2018.05.005","volume":"155","author":"S Chaudhuri","year":"2018","unstructured":"Chaudhuri S, Symons JA, Deval J (2018) Innovation and trends in the development and approval of antiviral medicines: 1987\u20132017 and beyond. Antiviral Res 155:76\u201388. https:\/\/doi.org\/10.1016\/j.antiviral.2018.05.005","journal-title":"Antiviral Res"},{"key":"3759_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.tips.2013.11.006","volume":"35","author":"Z Lou","year":"2014","unstructured":"Lou Z, Sun Y, Rao Z (2014) Current progress in antiviral strategies. Trends Pharmacol Sci 35:86\u2013102. https:\/\/doi.org\/10.1016\/j.tips.2013.11.006","journal-title":"Trends Pharmacol Sci"},{"key":"3759_CR13","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1007\/s00018-019-03138-w","volume":"76","author":"LCP Vilas Boas","year":"2019","unstructured":"Vilas Boas LCP, Campos ML, Berlanda RLA et al (2019) Antiviral peptides as promising therapeutic drugs. Cell Mol Life Sci 76:3525\u20133542. https:\/\/doi.org\/10.1007\/s00018-019-03138-w","journal-title":"Cell Mol Life Sci"},{"key":"3759_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semcdb.2018.03.001","volume":"88","author":"JR Shartouny","year":"2019","unstructured":"Shartouny JR, Jacob J (2019) Mining the tree of life: host defense peptides as antiviral therapeutics. Semin Cell Dev Biol 88:147\u2013155. https:\/\/doi.org\/10.1016\/j.semcdb.2018.03.001","journal-title":"Semin Cell Dev Biol"},{"key":"3759_CR15","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3389\/fimmu.2019.01366","volume":"10","author":"O Nyanguile","year":"2019","unstructured":"Nyanguile O (2019) Peptide antiviral strategies as an alternative to treat lower respiratory viral infections. Front Immunol 10:1366. https:\/\/doi.org\/10.3389\/fimmu.2019.01366","journal-title":"Front Immunol"},{"key":"3759_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/cbdd.12055","volume":"81","author":"DJ Craik","year":"2013","unstructured":"Craik DJ, Fairlie DP, Liras S, Price D (2013) The future of peptide-based drugs. Chem Biol Drug Des 81:136\u2013147. https:\/\/doi.org\/10.1111\/cbdd.12055","journal-title":"Chem Biol Drug Des"},{"key":"3759_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ejmech.2015.01.014","volume":"94","author":"N Tsomaia","year":"2015","unstructured":"Tsomaia N (2015) Peptide therapeutics: targeting the undruggable space. Eur J Med Chem 94:459\u2013470. https:\/\/doi.org\/10.1016\/j.ejmech.2015.01.014","journal-title":"Eur J Med Chem"},{"key":"3759_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1039\/c2np20085f","volume":"30","author":"PG Arnison","year":"2013","unstructured":"Arnison PG, Bibb MJ, Bierbaum G et al (2013) Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep 30:108\u2013160. https:\/\/doi.org\/10.1039\/c2np20085f","journal-title":"Nat Prod Rep"},{"key":"3759_CR19","doi-asserted-by":"publisher","DOI":"10.1039\/d0np00027b","author":"M Montalb\u00e1n-L\u00f3pez","year":"2021","unstructured":"Montalb\u00e1n-L\u00f3pez M, Scott TA, Ramesh S et al (2021) New developments in RiPP discovery, enzymology and engineering. Nat Prod Rep. https:\/\/doi.org\/10.1039\/d0np00027b","journal-title":"Nat Prod Rep"},{"key":"3759_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41589-019-0250-5","volume":"15","author":"S Schmitt","year":"2019","unstructured":"Schmitt S, Montalb\u00e1n-L\u00f3pez M, Peterhoff D et al (2019) Analysis of modular bioengineered antimicrobial lanthipeptides at nanoliter scale. Nat Chem Biol 15:437\u2013443. https:\/\/doi.org\/10.1038\/s41589-019-0250-5","journal-title":"Nat Chem Biol"},{"key":"3759_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/femsre\/fuw034","volume":"41","author":"M Montalb\u00e1n-L\u00f3pez","year":"2017","unstructured":"Montalb\u00e1n-L\u00f3pez M, van Heel AJ, Kuipers OP (2017) Employing the promiscuity of lantibiotic biosynthetic machineries to produce novel antimicrobials. FEMS Microbiol Rev 41:5\u201318. https:\/\/doi.org\/10.1093\/femsre\/fuw034","journal-title":"FEMS Microbiol Rev"},{"key":"3759_CR22","doi-asserted-by":"publisher","first-page":"W278","DOI":"10.1093\/nar\/gky383","volume":"46","author":"AJ Van Heel","year":"2018","unstructured":"Van Heel AJ, De Jong A, Song C et al (2018) BAGEL4: a user-friendly web server to thoroughly mine RiPPs and bacteriocins. Nucleic Acids Res 46:W278\u2013W281. https:\/\/doi.org\/10.1093\/nar\/gky383","journal-title":"Nucleic Acids Res"},{"key":"3759_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12917-019-2067-6","volume":"15","author":"J Ma\u0142aczewska","year":"2019","unstructured":"Ma\u0142aczewska J, Kaczorek-\u0141Ukowska E, W\u00f3jcik R, Krzysztof Siwicki A (2019) Antiviral effects of nisin, lysozyme, lactoferrin and their mixtures against bovine viral diarrhoea virus. BMC Vet Res 15:318. https:\/\/doi.org\/10.1186\/s12917-019-2067-6","journal-title":"BMC Vet Res"},{"key":"3759_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fmicb.2013.00046","volume":"4","author":"MH Ly-Chatain","year":"2013","unstructured":"Ly-Chatain MH, Moussaoui S, Vera A et al (2013) Antiviral effect of cationic compounds on bacteriophages. Front Microbiol 4:46. https:\/\/doi.org\/10.3389\/fmicb.2013.00046","journal-title":"Front Microbiol"},{"key":"3759_CR25","doi-asserted-by":"publisher","first-page":"14682","DOI":"10.1073\/pnas.1508095112","volume":"112","author":"AS Richard","year":"2015","unstructured":"Richard AS, Zhang A, Park SJ et al (2015) Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses. Proc Natl Acad Sci USA 112:14682\u201314687. https:\/\/doi.org\/10.1073\/pnas.1508095112","journal-title":"Proc Natl Acad Sci USA"},{"key":"3759_CR26","doi-asserted-by":"publisher","first-page":"837","DOI":"10.7164\/antibiotics.42.837","volume":"42","author":"N Naruse","year":"1989","unstructured":"Naruse N, Tenmyo O, Tomita K et al (1989) Lanthiopeptin, a new peptide antibiotic. Production, isolation and properties of lanthiopeptin. J Antibiot  (Tokyo) 42:837\u2013845. https:\/\/doi.org\/10.7164\/antibiotics.42.837","journal-title":"J Antibiot (Tokyo)"},{"key":"3759_CR27","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1529\/biophysj.106.101584","volume":"93","author":"K Iwamoto","year":"2007","unstructured":"Iwamoto K, Hayakawa T, Murate M et al (2007) Curvature-dependent recognition of ethanolamine phospholipids by duramycin and cinnamycin. Biophys J 93:1608\u20131619. https:\/\/doi.org\/10.1529\/biophysj.106.101584","journal-title":"Biophys J"},{"issue":"3","key":"3759_CR28","doi-asserted-by":"publisher","first-page":"e02698-16","DOI":"10.1128\/AEM.02698-16","volume":"83","author":"L Huo","year":"2017","unstructured":"Huo L, \u00d6kesli A, Zhao M, van der Donk WA (2017) Insights into the biosynthesis of duramycin. Appl Environ Microbiol 83(3):e02698-16. https:\/\/doi.org\/10.1128\/AEM.02698-16","journal-title":"Appl Environ Microbiol"},{"key":"3759_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1593\/neo.101366","volume":"13","author":"JH Stafford","year":"2011","unstructured":"Stafford JH, Thorpe PE (2011) Increased exposure of phosphatidylethanolamine on the surface of tumor vascular endothelium. Neoplasia 13:299\u2013308. https:\/\/doi.org\/10.1593\/neo.101366","journal-title":"Neoplasia"},{"key":"3759_CR30","doi-asserted-by":"publisher","first-page":"12570","DOI":"10.1021\/bi035225b","volume":"42","author":"G Machaidze","year":"2003","unstructured":"Machaidze G, Seelig J (2003) Specific binding of cinnamycin (Ro 09\u20130198) to phosphatidylethanolamine. Comparison between micellar and membrane environments. Biochemistry 42:12570\u201312576. https:\/\/doi.org\/10.1021\/bi035225b","journal-title":"Biochemistry"},{"key":"3759_CR31","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00726-009-0386-9","volume":"41","author":"M Zhao","year":"2011","unstructured":"Zhao M (2011) Lantibiotics as probes for phosphatidylethanolamine. Amino Acids 41:1071\u20131079. https:\/\/doi.org\/10.1007\/s00726-009-0386-9","journal-title":"Amino Acids"},{"key":"3759_CR32","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1242\/jcs.163105","volume":"128","author":"M Murate","year":"2015","unstructured":"Murate M, Abe M, Kasahara K et al (2015) Transbilayer distribution of lipids at nano scale. J Cell Sci 128:1627\u20131638. https:\/\/doi.org\/10.1242\/jcs.163105","journal-title":"J Cell Sci"},{"key":"3759_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.chom.2016.07.002","volume":"20","author":"T Tabata","year":"2016","unstructured":"Tabata T, Petitt M, Puerta-Guardo H et al (2016) Zika virus targets different primary human placental cells, suggesting two routes for vertical transmission. Cell Host Microbe 20:155\u2013166. https:\/\/doi.org\/10.1016\/j.chom.2016.07.002","journal-title":"Cell Host Microbe"},{"key":"3759_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1021\/acsinfecdis.5b00040","volume":"1","author":"PT Ivanova","year":"2016","unstructured":"Ivanova PT, Myers DS, Milne SB et al (2016) Lipid composition of the viral envelope of three strains of influenza virus\u2014not all viruses are created equal. ACS Infect Dis 1:435\u2013442. https:\/\/doi.org\/10.1021\/acsinfecdis.5b00040","journal-title":"ACS Infect Dis"},{"key":"3759_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a004820","volume":"3","author":"M Lorizate","year":"2011","unstructured":"Lorizate M, Kr\u00e4usslich HG (2011) Role of lipids in virus replication. Cold Spring Harb Perspect Biol 3:1\u201320. https:\/\/doi.org\/10.1101\/cshperspect.a004820","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"10","key":"3759_CR36","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.3390\/ijms21103544","volume":"21","author":"M Abu-Farha","year":"2020","unstructured":"Abu-Farha M, Thanaraj TA, Qaddoumi MG et al (2020) The role of lipid metabolism in COVID-19 virus infection and as a drug target. Int J Mol Sci 21(10):3544. https:\/\/doi.org\/10.3390\/ijms21103544","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3759_CR37","doi-asserted-by":"publisher","first-page":"e01471-19","DOI":"10.1128\/jvi.01471-19","volume":"94","author":"H Prochnow","year":"2019","unstructured":"Prochnow H, Rox K, Birudukota NVS et al (2019) Labyrinthopeptins exert broad-spectrum antiviral activity through lipid-binding-mediated virolysis. J Virol 94(2):e01471-19. https:\/\/doi.org\/10.1128\/jvi.01471-19","journal-title":"J Virol"},{"issue":"7 Supplement","key":"3759_CR38","first-page":"1053","volume":"64","author":"J He","year":"2004","unstructured":"He J, Thorpe PE (2004) Anti-tumor effects of duramycin-IgG conjugate. Cancer Res 64(7 Supplement):1053","journal-title":"Cancer Res"},{"key":"3759_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0005-2736(88)90192-7","volume":"940","author":"SY Choung","year":"1988","unstructured":"Choung SY, Kobayashi T, InoueYahara JI et al (1988) Hemolytic activity of a cyclic peptide Ro09-0198 isolated from Streptoverticillium. BBA-Biomembr 940:171\u2013179. https:\/\/doi.org\/10.1016\/0005-2736(88)90192-7","journal-title":"BBA-Biomembr"},{"key":"3759_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nchembio.2537","volume":"14","author":"TE Smith","year":"2018","unstructured":"Smith TE, Pond CD, Pierce E et al (2018) Accessing chemical diversity from the uncultivated symbionts of small marine animals. Nat Chem Biol 14:179\u2013185. https:\/\/doi.org\/10.1038\/nchembio.2537","journal-title":"Nat Chem Biol"},{"key":"3759_CR41","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1099\/ijs.0.02286-0","volume":"53","author":"J Wink","year":"2003","unstructured":"Wink J, Kroppenstedt RM, Seibert G, Stackebrandt E (2003) Actinomadura namibiensis sp. nov. Int J Syst Evol Microbiol 53:721\u2013724. https:\/\/doi.org\/10.1099\/ijs.0.02286-0","journal-title":"Int J Syst Evol Microbiol"},{"key":"3759_CR42","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/anie.200905773","volume":"49","author":"K Meindl","year":"2010","unstructured":"Meindl K, Schmiederer T, Schneider K et al (2010) Labyrinthopeptins: a new class of carbacyclic lantibiotics. Angew Chemie-Int Ed 49:1151\u20131154. https:\/\/doi.org\/10.1002\/anie.200905773","journal-title":"Angew Chemie-Int Ed"},{"issue":"5","key":"3759_CR43","doi-asserted-by":"publisher","first-page":"e64010","DOI":"10.1371\/journal.pone.0064010","volume":"8","author":"G F\u00e9rir","year":"2013","unstructured":"F\u00e9rir G, Petrova MI, Andrei G et al (2013) The lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applications. PLoS ONE 8(5):e64010. https:\/\/doi.org\/10.1371\/journal.pone.0064010","journal-title":"PLoS ONE"},{"key":"3759_CR44","doi-asserted-by":"publisher","first-page":"104774","DOI":"10.1016\/j.antiviral.2020.104774","volume":"177","author":"S Blockus","year":"2020","unstructured":"Blockus S, Sake SM, Wetzke M et al (2020) Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry. Antiviral Res 177:104774. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104774","journal-title":"Antiviral Res"},{"key":"3759_CR45","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1021\/acs.accounts.5b00156","volume":"48","author":"JD Hegemann","year":"2015","unstructured":"Hegemann JD, Zimmermann M, Xie X, Marahiel MA (2015) Lasso peptides: an intriguing class of bacterial natural products. Acc Chem Res 48:1909\u20131919. https:\/\/doi.org\/10.1021\/acs.accounts.5b00156","journal-title":"Acc Chem Res"},{"key":"3759_CR46","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/nchembio.2319","volume":"13","author":"JI Tietz","year":"2017","unstructured":"Tietz JI, Schwalen CJ, Patel PS et al (2017) A new genome-mining tool redefines the lasso peptide biosynthetic landscape. Nat Chem Biol 13:470\u2013478. https:\/\/doi.org\/10.1038\/nchembio.2319","journal-title":"Nat Chem Biol"},{"key":"3759_CR47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF00211754","volume":"5","author":"KL Constantine","year":"1995","unstructured":"Constantine KL, Friedrichs MS, Detlefsen D et al (1995) High-resolution solution structure of siamycin II: novel amphipathic character of a 21-residue peptide that inhibits HIV fusion. J Biomol NMR 5:271\u2013286. https:\/\/doi.org\/10.1007\/BF00211754","journal-title":"J Biomol NMR"},{"key":"3759_CR48","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1016\/j.bmc.2018.11.007","volume":"26","author":"I Kaweewan","year":"2018","unstructured":"Kaweewan I, Hemmi H, Komaki H et al (2018) Isolation and structure determination of a new lasso peptide specialicin based on genome mining. Bioorganic Med Chem 26:6050\u20136055. https:\/\/doi.org\/10.1016\/j.bmc.2018.11.007","journal-title":"Bioorganic Med Chem"},{"key":"3759_CR49","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1128\/AAC.39.10.2345","volume":"39","author":"S Chokekijchai","year":"1995","unstructured":"Chokekijchai S, Kojima E, Anderson S et al (1995) NP-06: a novel anti-human immunodeficiency virus polypeptide produced by a Streptomyces species. Antimicrob Agents Chemother 39:2345\u20132347. https:\/\/doi.org\/10.1128\/AAC.39.10.2345","journal-title":"Antimicrob Agents Chemother"},{"key":"3759_CR50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1021\/bi00167a006","volume":"33","author":"D Fr\u00e9chet","year":"1994","unstructured":"Fr\u00e9chet D, Guitton JD, Herman F et al (1994) Solution structure of RP 71955, a new 21 amino acid tricyclic peptide active against HIV-1 virus. Biochemistry 33:42\u201350. https:\/\/doi.org\/10.1021\/bi00167a006","journal-title":"Biochemistry"},{"issue":"20","key":"3759_CR51","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1007\/s00018-008-8147-6","volume":"65","author":"H Garg","year":"2008","unstructured":"Garg H, Blumenthal R (2008) Role of HIV Gp41 mediated fusion\/hemifusion in bystander apoptosis. Cell Mol Life Sci 65(20):3134\u20133144. https:\/\/doi.org\/10.1007\/s00018-008-8147-6","journal-title":"Cell Mol Life Sci"},{"key":"3759_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0092-8674(88)90487-4","volume":"53","author":"JM McCune","year":"1988","unstructured":"McCune JM, Rabin LB, Feinberg MB et al (1988) Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 53:55\u201367. https:\/\/doi.org\/10.1016\/0092-8674(88)90487-4","journal-title":"Cell"},{"key":"3759_CR53","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","volume":"89","author":"DC Chan","year":"1997","unstructured":"Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263\u2013273. https:\/\/doi.org\/10.1016\/S0092-8674(00)80205-6","journal-title":"Cell"},{"issue":"8","key":"3759_CR54","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3390\/v11080705","volume":"11","author":"J Pu","year":"2019","unstructured":"Pu J, Wang Q, Xu W et al (2019) Development of protein-and peptide-based HIV entry inhibitors targeting gp120 or gp41. Viruses 11(8):705. https:\/\/doi.org\/10.3390\/v11080705","journal-title":"Viruses"},{"key":"3759_CR55","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd1331","volume":"3","author":"T Matthews","year":"2004","unstructured":"Matthews T, Salgo M, Greenberg M et al (2004) Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3:215\u2013225. https:\/\/doi.org\/10.1038\/nrd1331","journal-title":"Nat Rev Drug Discov"},{"key":"3759_CR56","doi-asserted-by":"publisher","first-page":"433","DOI":"10.7164\/antibiotics.48.433","volume":"48","author":"M Tsunakawa","year":"1995","unstructured":"Tsunakawa M, Hu SL, Hoshino Y et al (1995) Siamycins I and II, new anti-HIV peptides: I. Fermentation, isolation, biological activity and initial characterization. J Antibiot (Tokyo) 48:433\u2013434. https:\/\/doi.org\/10.7164\/antibiotics.48.433","journal-title":"J Antibiot (Tokyo)"},{"key":"3759_CR57","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1128\/aac.40.1.133","volume":"40","author":"PF Lin","year":"1996","unstructured":"Lin PF, Samanta H, Bechtold CM et al (1996) Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor. Antimicrob Agents Chemother 40:133\u2013138. https:\/\/doi.org\/10.1128\/aac.40.1.133","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3759_CR58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/antibiotics9020067","volume":"9","author":"M S\u00e1nchez-Hidalgo","year":"2020","unstructured":"S\u00e1nchez-Hidalgo M, Mart\u00edn J, Genilloud O (2020) Identification and heterologous expression of the biosynthetic gene cluster encoding the lasso peptide humidimycin, a caspofungin activity potentiator. Antibiotics 9(2):67. https:\/\/doi.org\/10.3390\/antibiotics9020067","journal-title":"Antibiotics"},{"key":"3759_CR59","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/bip.20886","volume":"90","author":"DC Ireland","year":"2008","unstructured":"Ireland DC, Wang CKL, Wilson JA et al (2008) Cyclotides as natural anti-HIV agents. Biopolym - Pept Sci Sect 90:51\u201360. https:\/\/doi.org\/10.1002\/bip.20886","journal-title":"Biopolym - Pept Sci Sect"},{"key":"3759_CR60","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/10611860600648254","volume":"14","author":"M Werle","year":"2006","unstructured":"Werle M, Schmitz T, Huang HL et al (2006) The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery. J Drug Target 14:137\u2013146. https:\/\/doi.org\/10.1080\/10611860600648254","journal-title":"J Drug Target"},{"key":"3759_CR61","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2174\/1389203043379468","volume":"5","author":"K Gustafson","year":"2005","unstructured":"Gustafson K, McKee T, Bokesch H (2005) Anti-HIV cyclotides. Curr Protein Pept Sci 5:331\u2013340. https:\/\/doi.org\/10.2174\/1389203043379468","journal-title":"Curr Protein Pept Sci"},{"key":"3759_CR62","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.1021\/ja00099a064","volume":"116","author":"KR Gustafson","year":"1994","unstructured":"Gustafson KR, Parsons IC, Kashman Y et al (1994) Circulins A and B: novel HlV-inhibitory macrocyclic peptides from the tropical tree Chassalia parnifolia. J Am Chem Soc 116:9337\u20139338. https:\/\/doi.org\/10.1021\/ja00099a064","journal-title":"J Am Chem Soc"},{"key":"3759_CR63","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1006\/jmbi.1999.3383","volume":"294","author":"DJ Craik","year":"1999","unstructured":"Craik DJ, Daly NL, Bond T, Waine C (1999) Plant cyclotides: a unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif. J Mol Biol 294:1327\u20131336. https:\/\/doi.org\/10.1006\/jmbi.1999.3383","journal-title":"J Mol Biol"},{"issue":"3","key":"3759_CR64","doi-asserted-by":"publisher","first-page":"e91430","DOI":"10.1371\/journal.pone.0091430","volume":"9","author":"S Park","year":"2014","unstructured":"Park S, Str\u00f6mstedt AA, G\u00f6ransson U (2014) Cyclotide structure-activity relationships: qualitative and quantitative approaches linking cytotoxic and anthelmintic activity to the clustering of physicochemical forces. PLoS ONE 9(3):e91430. https:\/\/doi.org\/10.1371\/journal.pone.0091430","journal-title":"PLoS ONE"},{"key":"3759_CR65","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1021\/jo990952r","volume":"65","author":"YF Hallock","year":"2000","unstructured":"Hallock YF, Sowder RC, Pannell LK et al (2000) Cycloviolins A-D, anti-HIV macrocyclic peptides from Leonia cymosa. J Org Chem 65:124\u2013128. https:\/\/doi.org\/10.1021\/jo990952r","journal-title":"J Org Chem"},{"key":"3759_CR66","doi-asserted-by":"publisher","first-page":"22395","DOI":"10.1074\/jbc.M501737200","volume":"280","author":"B Chen","year":"2005","unstructured":"Chen B, Colgrave ML, Daly NL et al (2005) Isolation and characterization of novel cyclotides from Viola hederaceae: Solution structure and anti-HIV activity of vhl-1, a leaf-specific expressed cyclotide. J Biol Chem 280:22395\u201322405. https:\/\/doi.org\/10.1074\/jbc.M501737200","journal-title":"J Biol Chem"},{"key":"3759_CR67","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1021\/np990432r","volume":"63","author":"KR Gustafson","year":"2000","unstructured":"Gustafson KR, Walton LK, Sowder RC et al (2000) New circulin macrocyclic polypeptides from Chassalia parvifolia. J Nat Prod 63:176\u2013178. https:\/\/doi.org\/10.1021\/np990432r","journal-title":"J Nat Prod"},{"key":"3759_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20060627","volume":"400","author":"DC Ireland","year":"2006","unstructured":"Ireland DC, Colgrave ML, Craik DJ (2006) A novel suite of cyclotides from Viola odorata: sequence variation and the implications for structure, function and stability. Biochem J 400:1\u201312. https:\/\/doi.org\/10.1042\/BJ20060627","journal-title":"Biochem J"},{"key":"3759_CR69","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/np070393g","volume":"71","author":"CKL Wang","year":"2008","unstructured":"Wang CKL, Colgrave ML, Gustafson KR et al (2008) Anti-HIV cyclotides from the Chinese medicinal herb Viola yedoensis. J Nat Prod 71:47\u201352. https:\/\/doi.org\/10.1021\/np070393g","journal-title":"J Nat Prod"},{"key":"3759_CR70","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.str.2005.02.013","volume":"13","author":"JP Mulvenna","year":"2005","unstructured":"Mulvenna JP, Sando L, Craik DJ (2005) Processing of a 22 kDa precursor protein to produce the circular protein tricyclon A. Structure 13:691\u2013701. https:\/\/doi.org\/10.1016\/j.str.2005.02.013","journal-title":"Structure"},{"key":"3759_CR71","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/bip.22325","volume":"100","author":"SL Gerlach","year":"2013","unstructured":"Gerlach SL, Yeshak M, G\u00f6ransson U et al (2013) Cycloviolacin O2 (CyO2) suppresses productive infection and augments the antiviral efficacy of nelfinavir in HIV-1 infected monocytic cells. Biopolymers 100:471\u2013479. https:\/\/doi.org\/10.1002\/bip.22325","journal-title":"Biopolymers"},{"key":"3759_CR72","first-page":"905","volume":"49","author":"MZ Liu","year":"2014","unstructured":"Liu MZ, Yang Y, Zhang SX et al (2014) A cyclotide against influenza A H1N1 virus from Viola yedoensis. Yaoxue Xuebao 49:905\u2013912","journal-title":"Yaoxue Xuebao"},{"key":"3759_CR73","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.2174\/138161211798999438","volume":"17","author":"A Gould","year":"2012","unstructured":"Gould A, Ji Y, AboyeCamarero TLJA (2012) Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery. Curr Pharm Des 17:4294\u20134307. https:\/\/doi.org\/10.2174\/138161211798999438","journal-title":"Curr Pharm Des"},{"key":"3759_CR74","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.febslet.2004.08.007","volume":"574","author":"NL Daly","year":"2004","unstructured":"Daly NL, Gustafson KR, Craik DJ (2004) The role of the cyclic peptide backbone in the anti-HIV activity of the cyclotide kalata B1. FEBS Lett 574:69\u201372. https:\/\/doi.org\/10.1016\/j.febslet.2004.08.007","journal-title":"FEBS Lett"},{"key":"3759_CR75","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1021\/np9803878","volume":"62","author":"U G\u00f6ransson","year":"1999","unstructured":"G\u00f6ransson U, Luijendijk T, Johansson S et al (1999) Seven novel macrocyclic polypeptides from Viola arvensis. J Nat Prod 62:283\u2013286. https:\/\/doi.org\/10.1021\/np9803878","journal-title":"J Nat Prod"},{"key":"3759_CR76","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.1021\/bi9929756","volume":"39","author":"JF Hernandez","year":"2000","unstructured":"Hernandez JF, Gagnon J, Chiche L et al (2000) Squash trypsin inhibitors from Momordica cochinchinensis exhibit an atypical macrocyclic structure. Biochemistry 39:5722\u20135730. https:\/\/doi.org\/10.1021\/bi9929756","journal-title":"Biochemistry"},{"key":"3759_CR77","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1042\/BJ20051371","volume":"393","author":"NL Daly","year":"2006","unstructured":"Daly NL, Clark RJ, Plan MR, Craik DJ (2006) Kalata B8, a novel antiviral circular protein, exhibits conformational flexibility in the cystine knot motif. Biochem J 393:619\u2013626. https:\/\/doi.org\/10.1042\/BJ20051371","journal-title":"Biochem J"},{"key":"3759_CR78","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1021\/np000372l","volume":"64","author":"HR Bokesch","year":"2001","unstructured":"Bokesch HR, Pannell LK, Cochran PK et al (2001) A novel anti-HIV macrocyclic peptide from Palicourea condensata. J Nat Prod 64:249\u2013250. https:\/\/doi.org\/10.1021\/np000372l","journal-title":"J Nat Prod"},{"key":"3759_CR79","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/medicines6010033","volume":"6","author":"S Gerlach","year":"2019","unstructured":"Gerlach S, Chandra P, Roy U et al (2019) The membrane-active phytopeptide cycloviolacin O2 simultaneously targets HIV-1-infected cells and infectious viral particles to potentiate the efficacy of antiretroviral drugs. Medicines 6:33. https:\/\/doi.org\/10.3390\/medicines6010033","journal-title":"Medicines"},{"key":"3759_CR80","doi-asserted-by":"publisher","first-page":"24231","DOI":"10.1074\/jbc.M111.253393","volume":"286","author":"ST Henriques","year":"2011","unstructured":"Henriques ST, Huang YH, Rosengren KJ et al (2011) Decoding the membrane activity of the cyclotide kalata B1: the importance of phosphatidylethanolamine phospholipids and lipid organization on hemolytic and anti-HIV activities. J Biol Chem 286:24231\u201324241. https:\/\/doi.org\/10.1074\/jbc.M111.253393","journal-title":"J Biol Chem"},{"key":"3759_CR81","doi-asserted-by":"publisher","first-page":"33629","DOI":"10.1074\/jbc.M112.372011","volume":"287","author":"ST Henriques","year":"2012","unstructured":"Henriques ST, Huang YH, Castanho MARB et al (2012) Phosphatidylethanolamine binding is a conserved feature of cyclotide-membrane interactions. J Biol Chem 287:33629\u201333643. https:\/\/doi.org\/10.1074\/jbc.M112.372011","journal-title":"J Biol Chem"},{"key":"3759_CR82","doi-asserted-by":"publisher","first-page":"20699","DOI":"10.1074\/jbc.M109.003384","volume":"284","author":"YH Huang","year":"2009","unstructured":"Huang YH, Colgrave ML, Daly NL et al (2009) The biological activity of the prototypic cyclotide kalata B1 is modulated by the formation of multimeric pores. J Biol Chem 284:20699\u201320707. https:\/\/doi.org\/10.1074\/jbc.M109.003384","journal-title":"J Biol Chem"},{"key":"3759_CR83","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1039\/c0ob00966k","volume":"9","author":"R Burman","year":"2011","unstructured":"Burman R, Herrmann A, Tran R et al (2011) Cytotoxic potency of small macrocyclic knot proteins: structure-activity and mechanistic studies of native and chemically modified cyclotides. Org Biomol Chem 9:4306\u20134314. https:\/\/doi.org\/10.1039\/c0ob00966k","journal-title":"Org Biomol Chem"},{"key":"3759_CR84","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.bpj.2009.06.032","volume":"97","author":"CK Wang","year":"2009","unstructured":"Wang CK, Colgrave ML, Ireland DC et al (2009) Despite a conserved cystine knot motif, different cyclotides have different membrane binding modes. Biophys J 97:1471\u20131481. https:\/\/doi.org\/10.1016\/j.bpj.2009.06.032","journal-title":"Biophys J"},{"key":"3759_CR85","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1016\/j.bbamem.2011.07.004","volume":"1808","author":"R Burman","year":"2011","unstructured":"Burman R, Str\u00f6mstedt AA, Malmsten M, G\u00f6ransson U (2011) Cyclotide-membrane interactions: defining factors of membrane binding, depletion and disruption. Biochim Biophys Acta-Biomembr 1808:2665\u20132673. https:\/\/doi.org\/10.1016\/j.bbamem.2011.07.004","journal-title":"Biochim Biophys Acta-Biomembr"},{"key":"3759_CR86","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.plipres.2015.02.003","volume":"59","author":"DA Phoenix","year":"2015","unstructured":"Phoenix DA, Harris F, Mura M, Dennison SR (2015) The increasing role of phosphatidylethanolamine as a lipid receptor in the action of host defence peptides. Prog Lipid Res 59:26\u201337. https:\/\/doi.org\/10.1016\/j.plipres.2015.02.003","journal-title":"Prog Lipid Res"},{"key":"3759_CR87","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/cbic.201700153","volume":"18","author":"A Gould","year":"2017","unstructured":"Gould A, Camarero JA (2017) Cyclotides: overview and biotechnological applications. ChemBioChem 18:1350\u20131363. https:\/\/doi.org\/10.1002\/cbic.201700153","journal-title":"ChemBioChem"},{"key":"3759_CR88","doi-asserted-by":"publisher","first-page":"11763","DOI":"10.1002\/anie.201916321","volume":"59","author":"NM B\u00f6sch","year":"2020","unstructured":"B\u00f6sch NM, Borsa M, Greczmiel U et al (2020) Landornamides: antiviral ornithine-containing ribosomal peptides discovered through genome mining. Angew Chemie-Int Ed 59:11763\u201311768. https:\/\/doi.org\/10.1002\/anie.201916321","journal-title":"Angew Chemie-Int Ed"},{"key":"3759_CR89","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3201\/eid1303.061141","volume":"13","author":"S Emonet","year":"2007","unstructured":"Emonet S, Retornaz K, Gonzalez JP et al (2007) Mouse-to-human transmission of variant lymphocytic choriomeningitis virus. Emerg Infect Dis 13:472\u2013475. https:\/\/doi.org\/10.3201\/eid1303.061141","journal-title":"Emerg Infect Dis"},{"key":"3759_CR90","doi-asserted-by":"publisher","first-page":"7246","DOI":"10.1128\/jvi.00614-11","volume":"85","author":"H Moreno","year":"2011","unstructured":"Moreno H, Gallego I, Sevilla N et al (2011) Ribavirin can be mutagenic for arenaviruses. J Virol 85:7246\u20137255. https:\/\/doi.org\/10.1128\/jvi.00614-11","journal-title":"J Virol"},{"key":"3759_CR91","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/md12010317","volume":"12","author":"X Just-Baringo","year":"2014","unstructured":"Just-Baringo X, Albericio F, \u00c1lvarez M (2014) Thiopeptide antibiotics: retrospective and recent advances. Mar Drugs 12:317\u2013351. https:\/\/doi.org\/10.3390\/md12010317","journal-title":"Mar Drugs"},{"key":"3759_CR92","doi-asserted-by":"publisher","first-page":"9494","DOI":"10.1021\/jacs.8b03896","volume":"140","author":"CJ Schwalen","year":"2018","unstructured":"Schwalen CJ, Hudson GA, Kille B, Mitchell DA (2018) Bioinformatic expansion and discovery of thiopeptide antibiotics. J Am Chem Soc 140:9494\u20139501. https:\/\/doi.org\/10.1021\/jacs.8b03896","journal-title":"J Am Chem Soc"},{"key":"3759_CR93","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.antiviral.2016.07.002","volume":"132","author":"M Lee","year":"2016","unstructured":"Lee M, Yang J, Park S et al (2016) Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner. Antiviral Res 132:287\u2013295. https:\/\/doi.org\/10.1016\/j.antiviral.2016.07.002","journal-title":"Antiviral Res"},{"key":"3759_CR94","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12602-012-9123-x","volume":"5","author":"NI Torres","year":"2013","unstructured":"Torres NI, Noll KS, Xu S et al (2013) Safety, formulation and in vitro antiviral activity of the antimicrobial peptide subtilosin against herpes simplex virus type 1. Probiotics Antimicrob Proteins 5:26\u201335. https:\/\/doi.org\/10.1007\/s12602-012-9123-x","journal-title":"Probiotics Antimicrob Proteins"},{"key":"3759_CR95","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/jam.12618","volume":"117","author":"VM Quintana","year":"2014","unstructured":"Quintana VM, Torres NI, Wachsman MB et al (2014) Antiherpes simplex virus type 2 activity of the antimicrobial peptide subtilosin. J Appl Microbiol 117:1253\u20131259. https:\/\/doi.org\/10.1111\/jam.12618","journal-title":"J Appl Microbiol"},{"key":"3759_CR96","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/cbic.201900511","volume":"21","author":"CM Crnkovic","year":"2020","unstructured":"Crnkovic CM, Braesel J, Krunic A et al (2020) Scytodecamide from the cultured scytonema sp. UIC 10036 expands the chemical and genetic diversity of cyanobactins. ChemBioChem 21:845\u2013852. https:\/\/doi.org\/10.1002\/cbic.201900511","journal-title":"ChemBioChem"},{"key":"3759_CR97","unstructured":"Mander L, Liu HW (2010) Comprehensive Natural Products II: Chemistry and Biology"},{"key":"3759_CR98","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1021\/jm9806650","volume":"42","author":"MVR Reddy","year":"1999","unstructured":"Reddy MVR, Rao MR, Rhodes D et al (1999) Lamellarin \u03b1 20-sulfate, an inhibitor of HIV-1 integrase active against HIV-1 virus in cell culture. J Med Chem 42:1901\u20131907. https:\/\/doi.org\/10.1021\/jm9806650","journal-title":"J Med Chem"},{"key":"3759_CR99","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1021\/np990353f","volume":"63","author":"SS Mitchell","year":"2000","unstructured":"Mitchell SS, Faulkner DJ, Rubins K, Bushman FD (2000) Dolastatin 3 and two novel cyclic peptides from a palauan collection of Lyngbya majuscula. J Nat Prod 63:279\u2013282. https:\/\/doi.org\/10.1021\/np990353f","journal-title":"J Nat Prod"},{"key":"3759_CR100","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/17460441.2017.1303478","volume":"12","author":"MM Zhang","year":"2017","unstructured":"Zhang MM, Qiao Y, Ang EL, Zhao H (2017) Using natural products for drug discovery: the impact of the genomics era. Expert Opin Drug Discov 12:475\u2013487. https:\/\/doi.org\/10.1080\/17460441.2017.1303478","journal-title":"Expert Opin Drug Discov"},{"key":"3759_CR101","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1039\/c6np00025h","volume":"33","author":"N Ziemert","year":"2016","unstructured":"Ziemert N, Alanjary M, Weber T (2016) The evolution of genome mining in microbes-a review. Nat Prod Rep 33:988\u20131005. https:\/\/doi.org\/10.1039\/c6np00025h","journal-title":"Nat Prod Rep"},{"key":"3759_CR102","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3389\/fmicb.2018.01801","volume":"9","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Chen M, Bruner SD, Ding Y (2018) Heterologous production of microbial ribosomally synthesized and post-translationally modified peptides. Front Microbiol 9:1801. https:\/\/doi.org\/10.3389\/fmicb.2018.01801","journal-title":"Front Microbiol"},{"key":"3759_CR103","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1021\/sb500267d","volume":"4","author":"DE Ruffner","year":"2015","unstructured":"Ruffner DE, Schmidt EW, Heemstra JR (2015) Assessing the combinatorial potential of the RiPP cyanobactin tru pathway. ACS Synth Biol 4:482\u2013492. https:\/\/doi.org\/10.1021\/sb500267d","journal-title":"ACS Synth Biol"},{"key":"3759_CR104","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1007\/s00253-019-09893-x","volume":"103","author":"E Vogt","year":"2019","unstructured":"Vogt E, K\u00fcnzler M (2019) Discovery of novel fungal RiPP biosynthetic pathways and their application for the development of peptide therapeutics. Appl Microbiol Biotechnol 103:5567\u20135581. https:\/\/doi.org\/10.1007\/s00253-019-09893-x","journal-title":"Appl Microbiol Biotechnol"},{"key":"3759_CR105","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.mib.2018.02.010","volume":"45","author":"GA Hudson","year":"2018","unstructured":"Hudson GA, Mitchell DA (2018) RiPP antibiotics: biosynthesis and engineering potential. Curr Opin Microbiol 45:61\u201369. https:\/\/doi.org\/10.1016\/j.mib.2018.02.010","journal-title":"Curr Opin Microbiol"},{"key":"3759_CR106","doi-asserted-by":"publisher","first-page":"24340","DOI":"10.1016\/s0021-9258(18)35771-5","volume":"267","author":"OP Kuipers","year":"1992","unstructured":"Kuipers OP, Rollema HS, Yap WMGJ et al (1992) Engineering dehydrated amino acid residues in the antimicrobial peptide nisin. J Biol Chem 267:24340\u201324346. https:\/\/doi.org\/10.1016\/s0021-9258(18)35771-5","journal-title":"J Biol Chem"},{"key":"3759_CR107","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1021\/sb3001084","volume":"2","author":"AJ Van Heel","year":"2013","unstructured":"Van Heel AJ, Mu D, Montalb\u00e1n-L\u00f3pez M et al (2013) Designing and producing modified, new-to-nature peptides with antimicrobial activity by use of a combination of various lantibiotic modification enzymes. ACS Synth Biol 2:397\u2013404. https:\/\/doi.org\/10.1021\/sb3001084","journal-title":"ACS Synth Biol"},{"key":"3759_CR108","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.bmc.2009.12.026","volume":"18","author":"Y Gao","year":"2010","unstructured":"Gao Y, Cui T, Lam Y (2010) Synthesis and disulfide bond connectivity-activity studies of a kalata B1-inspired cyclopeptide against dengue NS2B-NS3 protease. Bioorg Med Chem 18:1331\u20131336. https:\/\/doi.org\/10.1016\/j.bmc.2009.12.026","journal-title":"Bioorg Med Chem"},{"key":"3759_CR109","doi-asserted-by":"publisher","first-page":"10729","DOI":"10.1021\/jm301468k","volume":"55","author":"TL Aboye","year":"2012","unstructured":"Aboye TL, Ha H, Majumder S et al (2012) Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. J Med Chem 55:10729\u201310734. https:\/\/doi.org\/10.1021\/jm301468k","journal-title":"J Med Chem"},{"key":"3759_CR110","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1039\/b801667d","volume":"6","author":"P Thongyoo","year":"2008","unstructured":"Thongyoo P, Roqu\u00e9-Rosell N, Leatherbarrow RJ, Tate EW (2008) Chemical and biomimetic total syntheses of natural and engineered MCoTI cyclotides. Org Biomol Chem 6:1462\u20131470. https:\/\/doi.org\/10.1039\/b801667d","journal-title":"Org Biomol Chem"},{"issue":"11","key":"3759_CR111","doi-asserted-by":"publisher","first-page":"e0139562","DOI":"10.1371\/journal.pone.0139562","volume":"10","author":"A Sangphukieo","year":"2015","unstructured":"Sangphukieo A, Nawae W, Laomettachit T et al (2015) Computational design of hypothetical new peptides based on a cyclotide scaffold as HIV gp120 inhibitor. PLoS ONE 10(11):e0139562. https:\/\/doi.org\/10.1371\/journal.pone.0139562","journal-title":"PLoS ONE"},{"key":"3759_CR112","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1021\/acssynbio.6b00033","volume":"5","author":"AJ Van Heel","year":"2016","unstructured":"Van Heel AJ, Kloosterman TG, Montalban-Lopez M et al (2016) Discovery, production and modification of five novel lantibiotics using the promiscuous nisin modification machinery. ACS Synth Biol 5:1146\u20131154. https:\/\/doi.org\/10.1021\/acssynbio.6b00033","journal-title":"ACS Synth Biol"},{"issue":"12","key":"3759_CR113","doi-asserted-by":"publisher","first-page":"e00052-18","DOI":"10.1128\/AEM.00052-18","volume":"84","author":"Q Li","year":"2018","unstructured":"Li Q, Montalban-Lopez M, Kuipers OP (2018) Increasing the antimicrobial activity of nisinbased lantibiotics against Gram-negative pathogens. Appl Environ Microbiol 84(12):e00052-18. https:\/\/doi.org\/10.1128\/AEM.00052-18","journal-title":"Appl Environ Microbiol"},{"key":"3759_CR114","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fcell.2016.00007","volume":"4","author":"L Zhou","year":"2016","unstructured":"Zhou L, van Heel AJ, Montalban-Lopez M, Kuipers OP (2016) Potentiating the activity of nisin against Escherichia coli. Front Cell Dev Biol 4:7. https:\/\/doi.org\/10.3389\/fcell.2016.00007","journal-title":"Front Cell Dev Biol"},{"key":"3759_CR115","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41589-018-0008-5","volume":"14","author":"X Yang","year":"2018","unstructured":"Yang X, Lennard KR, He C et al (2018) A lanthipeptide library used to identify a protein-protein interaction inhibitor article. Nat Chem Biol 14:375\u2013380. https:\/\/doi.org\/10.1038\/s41589-018-0008-5","journal-title":"Nat Chem Biol"},{"key":"3759_CR116","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1021\/cb800193n","volume":"3","author":"A Tavassoli","year":"2008","unstructured":"Tavassoli A, Lu Q, Gam J et al (2008) Inhibition of HIV budding by a genetically selected cyclic peptide targeting the Gag-TSG101 interaction. ACS Chem Biol 3:757\u2013764. https:\/\/doi.org\/10.1021\/cb800193n","journal-title":"ACS Chem Biol"},{"key":"3759_CR117","unstructured":"Us20190046604 Labyrinthopeptins as anti-viral agents. https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=US237388358&docAn=15776522 . Accessed 13 Dec 2020"},{"issue":"2","key":"3759_CR118","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/pharmaceutics12020171","volume":"12","author":"FD Cojocaru","year":"2020","unstructured":"Cojocaru FD, Botezat D, Gardikiotis I et al (2020) Nanomaterials designed for antiviral drug delivery transport across biological barriers. Pharmaceutics 12(2):171. https:\/\/doi.org\/10.3390\/pharmaceutics12020171","journal-title":"Pharmaceutics"},{"key":"3759_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-52733-0.00014-8","author":"M Milovanovic","year":"2017","unstructured":"Milovanovic M, Arsenijevic A, Milovanovic J et al (2017) Nanoparticles in antiviral therapy. In: antimicrobial nanoarchitectonics: from synthesis to applications. Antimicrobial Nanoarchitectonics. https:\/\/doi.org\/10.1016\/B978-0-323-52733-0.00014-8","journal-title":"Antimicrobial Nanoarchitectonics"},{"key":"3759_CR120","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/2049936117713593","volume":"4","author":"L Singh","year":"2017","unstructured":"Singh L, Kruger HG, Maguire GEM et al (2017) The role of nanotechnology in the treatment of viral infections. Ther Adv Infect Dis 4:105\u2013131. https:\/\/doi.org\/10.1177\/2049936117713593","journal-title":"Ther Adv Infect Dis"},{"key":"3759_CR121","unstructured":"Marimuthu P (2017) Oral delivery of therapeutic peptides using GCPQ nanoparticles. Dr thesis, UCL (University Coll London)"},{"issue":"329","key":"3759_CR122","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1126\/science.1193748","volume":"80","author":"QA Karim","year":"2010","unstructured":"Karim QA, Karim SSA, Frohlich JA et al (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 80(329):1168\u20131174. https:\/\/doi.org\/10.1126\/science.1193748","journal-title":"Science"},{"key":"3759_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules25061375","volume":"25","author":"X Lin","year":"2020","unstructured":"Lin X, Li X, Lin X (2020) A review on applications of computational methods in drug screening and design. Molecules 25:1\u201317. https:\/\/doi.org\/10.3390\/molecules25061375","journal-title":"Molecules"},{"key":"3759_CR124","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nrd1549","volume":"3","author":"DB Kitchen","year":"2004","unstructured":"Kitchen DB, Decornez H, Furr JR, Bajorath J (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 3:935\u2013949. https:\/\/doi.org\/10.1038\/nrd1549","journal-title":"Nat Rev Drug Discov"},{"key":"3759_CR125","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1021\/ml100288q","volume":"2","author":"N Levoin","year":"2011","unstructured":"Levoin N, Calmels T, Krief S et al (2011) Homology model versus X-ray structure in receptor-based drug design: a retrospective analysis with the dopamine D3 receptor. ACS Med Chem Lett 2:293\u2013297. https:\/\/doi.org\/10.1021\/ml100288q","journal-title":"ACS Med Chem Lett"},{"key":"3759_CR126","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.abb.2017.06.005","volume":"628","author":"MJ Harner","year":"2017","unstructured":"Harner MJ, Mueller L, Robbins KJ, Reily MD (2017) NMR in drug design. Arch Biochem Biophys 628:132\u2013147. https:\/\/doi.org\/10.1016\/j.abb.2017.06.005","journal-title":"Arch Biochem Biophys"},{"key":"3759_CR127","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1021\/acs.accounts.5b00338","volume":"48","author":"S Takada","year":"2015","unstructured":"Takada S, Kanada R, Tan C et al (2015) Modeling structural dynamics of biomolecular complexes by coarse-grained molecular simulations. Acc Chem Res 48:3026\u20133035. https:\/\/doi.org\/10.1021\/acs.accounts.5b00338","journal-title":"Acc Chem Res"},{"key":"3759_CR128","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/17460441.2019.1560261","volume":"14","author":"WJ Shin","year":"2019","unstructured":"Shin WJ, Seong BL (2019) Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains. Expert Opin Drug Discov 14:153\u2013168. https:\/\/doi.org\/10.1080\/17460441.2019.1560261","journal-title":"Expert Opin Drug Discov"},{"key":"3759_CR129","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1124\/pr.112.007336","volume":"66","author":"G Sliwoski","year":"2014","unstructured":"Sliwoski G, Kothiwale S, Meiler J, Lowe EW (2014) Computational methods in drug discovery. Pharmacol Rev 66:334\u2013395. https:\/\/doi.org\/10.1124\/pr.112.007336","journal-title":"Pharmacol Rev"},{"key":"3759_CR130","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","volume":"162","author":"JP Hughes","year":"2011","unstructured":"Hughes JP, Rees SS, Kalindjian SB, Philpott KL (2011) Principles of early drug discovery. Br J Pharmacol 162:1239\u20131249. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01127.x","journal-title":"Br J Pharmacol"},{"key":"3759_CR131","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1517\/17460441.3.6.671","volume":"3","author":"N Green","year":"2008","unstructured":"Green N, Ott RD, Isaacs RJ, Fang H (2008) Cell-based assays to identify inhibitors of viral disease. Expert Opin Drug Discov 3:671\u2013676. https:\/\/doi.org\/10.1517\/17460441.3.6.671","journal-title":"Expert Opin Drug Discov"},{"key":"3759_CR132","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/386410","author":"CT Lohans","year":"2012","unstructured":"Lohans CT, Vederas JC (2012) Development of class IIa bacteriocins as therapeutic agents. Int J Microbiol. https:\/\/doi.org\/10.1155\/2012\/386410","journal-title":"Int J Microbiol"},{"key":"3759_CR133","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1517\/17425255.2011.573478","volume":"7","author":"AJ Van Heel","year":"2011","unstructured":"Van Heel AJ, Montalban-Lopez M, Kuipers OP (2011) Evaluating the feasibility of lantibiotics as an alternative therapy against bacterial infections in humans. Expert Opin Drug Metab Toxicol 7:675\u2013680. https:\/\/doi.org\/10.1517\/17425255.2011.573478","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3759_CR134","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00210-008-0293-8","volume":"378","author":"I Steiner","year":"2008","unstructured":"Steiner I, Errhalt P, Kubesch K et al (2008) Pulmonary pharmacokinetics and safety of nebulized duramycin in healthy male volunteers. Naunyn Schmiedebergs Arch Pharmacol 378:323\u2013333. https:\/\/doi.org\/10.1007\/s00210-008-0293-8","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3759_CR135","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s12602-018-9457-0","volume":"11","author":"EI Ermolenko","year":"2019","unstructured":"Ermolenko EI, Desheva YA, Kolobov AA et al (2019) Anti-influenza activity of enterocin B in vitro and protective effect of bacteriocinogenic enterococcal probiotic strain on influenza infection in mouse model. Probiotics Antimicrob Proteins 11:705\u2013712. https:\/\/doi.org\/10.1007\/s12602-018-9457-0","journal-title":"Probiotics Antimicrob Proteins"},{"key":"3759_CR136","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/jam.13033","volume":"120","author":"JM Shin","year":"2016","unstructured":"Shin JM, Gwak JW, Kamarajan P et al (2016) Biomedical applications of nisin. J Appl Microbiol 120:1449\u20131465. https:\/\/doi.org\/10.1111\/jam.13033","journal-title":"J Appl Microbiol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-021-03759-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-021-03759-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-021-03759-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T01:18:34Z","timestamp":1620436714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-021-03759-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":136,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["3759"],"URL":"https:\/\/doi.org\/10.1007\/s00018-021-03759-0","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739484140.793583073","asserted-by":"object"}]},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"17 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}